US8329159B2
(en)
|
2006-08-11 |
2012-12-11 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8303944B2
(en)
*
|
2006-08-11 |
2012-11-06 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7759495B2
(en)
|
2006-08-11 |
2010-07-20 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7745636B2
(en)
|
2006-08-11 |
2010-06-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
ES2381410T3
(es)
|
2007-05-04 |
2012-05-28 |
Vertex Pharmceuticals Incorporated |
Terapia de combinación paa el tratamiento de infecciones por VHC
|
US7741347B2
(en)
|
2007-05-17 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
ES2569660T3
(es)
|
2007-06-08 |
2016-05-12 |
Mannkind Corporation |
Inhibidores de la IRE-1alfa
|
NZ582692A
(en)
*
|
2007-07-05 |
2012-05-25 |
Array Biopharma Inc |
Pyrimidyl cyclopentanes as akt protein kinase inhibitors
|
US8629171B2
(en)
|
2007-08-08 |
2014-01-14 |
Bristol-Myers Squibb Company |
Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
|
US7728027B2
(en)
*
|
2007-08-08 |
2010-06-01 |
Bristol-Myers Squibb Company |
Process for synthesizing compounds useful for treating hepatitis C
|
US8093243B2
(en)
|
2008-02-12 |
2012-01-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CN101998952B
(zh)
*
|
2008-02-12 |
2014-10-08 |
百时美施贵宝公司 |
丙型肝炎病毒抑制剂
|
US7704992B2
(en)
|
2008-02-13 |
2010-04-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8147818B2
(en)
*
|
2008-02-13 |
2012-04-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
JP5312486B2
(ja)
*
|
2008-02-13 |
2013-10-09 |
ブリストル−マイヤーズ スクイブ カンパニー |
C型肝炎ウイルス阻害剤
|
US7906655B2
(en)
|
2008-08-07 |
2011-03-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
KR101406433B1
(ko)
*
|
2008-09-22 |
2014-06-13 |
카이맨 케미칼 컴파니 인코포레이티드 |
H-pgds 억제제로서 다중헤테로아릴 화합물 및 프로스타글란딘 d2 매개된 질병의 치료를 위한 그의 용도
|
US8383094B2
(en)
|
2008-10-01 |
2013-02-26 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8729077B2
(en)
*
|
2008-11-28 |
2014-05-20 |
Glaxosmithkline Llc |
Anti-viral compounds, compositions, and methods of use
|
SG171891A1
(en)
*
|
2008-12-03 |
2011-07-28 |
Presidio Pharmaceuticals Inc |
Inhibitors of hcv ns5a
|
PT2373172E
(pt)
*
|
2008-12-03 |
2013-10-21 |
Presidio Pharmaceuticals Inc |
Inibidores de ns5a de hcv
|
JP2012513410A
(ja)
*
|
2008-12-23 |
2012-06-14 |
アボット・ラボラトリーズ |
抗ウイルス化合物
|
CN102264737A
(zh)
|
2008-12-23 |
2011-11-30 |
雅培制药有限公司 |
抗病毒化合物
|
US8637561B2
(en)
|
2009-02-17 |
2014-01-28 |
Enanta Pharmaceuticals, Inc. |
Linked diimidazole derivatives
|
US8242156B2
(en)
|
2009-02-17 |
2012-08-14 |
Enanta Pharmaceuticals, Inc. |
Linked dibenzimidazole derivatives
|
TWI438200B
(zh)
|
2009-02-17 |
2014-05-21 |
必治妥美雅史谷比公司 |
C型肝炎病毒抑制劑
|
US8394968B2
(en)
|
2009-02-17 |
2013-03-12 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8188132B2
(en)
|
2009-02-17 |
2012-05-29 |
Enanta Pharmaceuticals, Inc. |
Linked dibenzimidazole derivatives
|
US8420686B2
(en)
|
2009-02-17 |
2013-04-16 |
Enanta Pharmaceuticals, Inc. |
Linked diimidazole antivirals
|
CA2753313A1
(en)
*
|
2009-02-23 |
2010-08-26 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of hcv ns5a
|
US8101643B2
(en)
*
|
2009-02-27 |
2012-01-24 |
Enanta Pharmaceuticals, Inc. |
Benzimidazole derivatives
|
BRPI1007836A2
(pt)
*
|
2009-02-27 |
2015-09-01 |
Enanta Phamaceuticals Inc |
Inibidores do vírus c da hepatite
|
US8673954B2
(en)
|
2009-02-27 |
2014-03-18 |
Enanta Pharmaceuticals, Inc. |
Benzimidazole derivatives
|
US9765087B2
(en)
|
2009-02-27 |
2017-09-19 |
Enanta Pharmaceuticals, Inc. |
Benzimidazole derivatives
|
US8426458B2
(en)
|
2009-02-27 |
2013-04-23 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C Virus inhibitors
|
US10752611B2
(en)
|
2009-02-27 |
2020-08-25 |
Enanta Pharmaceuticals, Inc. |
Benzimidazole derivatives
|
US8507522B2
(en)
|
2009-03-06 |
2013-08-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
CN102448458B
(zh)
|
2009-03-18 |
2015-07-22 |
小利兰·斯坦福大学理事会 |
治疗黄病毒科病毒感染的方法和组合物
|
WO2010111534A1
(en)
*
|
2009-03-27 |
2010-09-30 |
Presidio Pharmaceuticals, Inc. |
Fused ring inhibitors of hepatitis c
|
EP2410841A4
(en)
|
2009-03-27 |
2012-10-24 |
Presidio Pharmaceuticals Inc |
SUBSTITUTED BICYCLIC HCV INHIBITORS
|
TWI476190B
(zh)
*
|
2009-03-30 |
2015-03-11 |
必治妥美雅史谷比公司 |
C型肝炎病毒抑制劑
|
US8796466B2
(en)
*
|
2009-03-30 |
2014-08-05 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
TW201038559A
(en)
|
2009-04-09 |
2010-11-01 |
Bristol Myers Squibb Co |
Hepatitis C virus inhibitors
|
US8143414B2
(en)
*
|
2009-04-13 |
2012-03-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CN102459165B
(zh)
*
|
2009-04-15 |
2015-09-02 |
Abbvie公司 |
抗病毒化合物
|
WO2010132538A1
(en)
*
|
2009-05-12 |
2010-11-18 |
Schering Corporation |
Fused tricyclic aryl compounds useful for the treatment of viral diseases
|
TW202042807A
(zh)
|
2009-05-13 |
2020-12-01 |
美商基利法瑪席特有限責任公司 |
抗病毒化合物
|
WO2010138791A1
(en)
|
2009-05-29 |
2010-12-02 |
Schering Corporation |
Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
|
US8211928B2
(en)
*
|
2009-05-29 |
2012-07-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8138215B2
(en)
|
2009-05-29 |
2012-03-20 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2435421A1
(en)
|
2009-05-29 |
2012-04-04 |
Schering Corporation |
Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
|
CN103819459B
(zh)
*
|
2009-06-11 |
2017-05-17 |
艾伯维巴哈马有限公司 |
抗病毒化合物
|
US8716454B2
(en)
|
2009-06-11 |
2014-05-06 |
Abbvie Inc. |
Solid compositions
|
US8937150B2
(en)
|
2009-06-11 |
2015-01-20 |
Abbvie Inc. |
Anti-viral compounds
|
US9394279B2
(en)
|
2009-06-11 |
2016-07-19 |
Abbvie Inc. |
Anti-viral compounds
|
US8221737B2
(en)
|
2009-06-16 |
2012-07-17 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
US8609648B2
(en)
|
2009-07-02 |
2013-12-17 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
WO2011004276A1
(en)
*
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
CA2767887A1
(en)
|
2009-07-16 |
2011-01-20 |
Vertex Pharmaceuticals Incorporated |
Benzimidazole analogues for the treatment or prevention of flavivirus infections
|
RU2538507C2
(ru)
|
2009-08-07 |
2015-01-10 |
Тиботек Фармасьютикалз |
Фенилэтинильные производные в качестве ингибиторов вируса гепатита с
|
CN102471324B
(zh)
|
2009-08-07 |
2014-12-17 |
泰博特克药品公司 |
作为丙型肝炎病毒抑制剂的双苯并咪唑衍生物
|
US20120172368A1
(en)
|
2009-09-03 |
2012-07-05 |
Koen Vandyck |
Bis-Benzimidazole Derivatives
|
EP3006441A1
(en)
|
2009-09-04 |
2016-04-13 |
Janssen Pharmaceuticals, Inc. |
Ns5a inhibitors
|
US8759332B2
(en)
*
|
2009-09-11 |
2014-06-24 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
EP2475254A4
(en)
*
|
2009-09-11 |
2013-05-22 |
Enanta Pharm Inc |
HEPATITIS C-VIRUS HEMMER
|
US8927709B2
(en)
*
|
2009-09-11 |
2015-01-06 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
US9156818B2
(en)
|
2009-09-11 |
2015-10-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
US8822700B2
(en)
*
|
2009-09-11 |
2014-09-02 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
US8703938B2
(en)
*
|
2009-09-11 |
2014-04-22 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
US8815928B2
(en)
|
2009-09-11 |
2014-08-26 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
UA108211C2
(ru)
|
2009-11-04 |
2015-04-10 |
Янссен Рід Айрленд |
Бензимидазолимидазольные производные
|
US20110269956A1
(en)
|
2009-11-11 |
2011-11-03 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US20110274648A1
(en)
|
2009-11-11 |
2011-11-10 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US20110281910A1
(en)
*
|
2009-11-12 |
2011-11-17 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
CA2782024A1
(en)
|
2009-11-25 |
2011-06-03 |
Schering Corporation |
Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
|
US20110137633A1
(en)
*
|
2009-12-03 |
2011-06-09 |
Abbott Laboratories |
Anti-viral compounds and methods of identifying the same
|
WO2011068941A2
(en)
|
2009-12-04 |
2011-06-09 |
National Health Research Institutes |
Proline derivatives
|
US8653070B2
(en)
*
|
2009-12-14 |
2014-02-18 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
US8377980B2
(en)
|
2009-12-16 |
2013-02-19 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
AU2010330862B2
(en)
*
|
2009-12-18 |
2015-06-25 |
Idenix Pharmaceuticals, Inc. |
5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
|
CN102791687B
(zh)
*
|
2009-12-18 |
2015-02-11 |
北京凯因科技股份有限公司 |
C型肝炎病毒复制的新型抑制剂
|
CN102753173A
(zh)
|
2009-12-18 |
2012-10-24 |
贝林格尔.英格海姆国际有限公司 |
Hcv组合疗法
|
JP2013515068A
(ja)
|
2009-12-22 |
2013-05-02 |
メルク・シャープ・アンド・ドーム・コーポレーション |
ウイルス性疾患の治療のための縮合三環式化合物およびその使用方法
|
JP2013515746A
(ja)
*
|
2009-12-24 |
2013-05-09 |
ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド |
フラビウイルス感染症の治療又は予防のための類似体
|
US8362020B2
(en)
|
2009-12-30 |
2013-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
KR20120107529A
(ko)
*
|
2010-01-25 |
2012-10-02 |
이난타 파마슈티칼스, 인코포레이티드 |
C형 간염 바이러스 억제제
|
US8933110B2
(en)
|
2010-01-25 |
2015-01-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
JP2013518062A
(ja)
*
|
2010-01-28 |
2013-05-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
C型肝炎阻害化合物
|
US8178531B2
(en)
|
2010-02-23 |
2012-05-15 |
Enanta Pharmaceuticals, Inc. |
Antiviral agents
|
US8623814B2
(en)
|
2010-02-23 |
2014-01-07 |
Enanta Pharmaceuticals, Inc. |
Antiviral agents
|
BR112012022311A2
(pt)
|
2010-03-04 |
2016-08-23 |
Enanta Pharm Inc |
agentes farmacêuticos de combinação como inibidores da replicação de hcv.
|
EA201290882A1
(ru)
*
|
2010-03-09 |
2013-04-30 |
Мерк Шарп Энд Домэ Корп. |
Конденсированные трициклические силильные соединения и способы их применения для лечения вирусных заболеваний
|
EP2550262A1
(en)
*
|
2010-03-24 |
2013-01-30 |
Vertex Pharmaceuticals Incorporated |
Analogues for the treatment or prevention of flavivirus infections
|
EP2550267A1
(en)
|
2010-03-24 |
2013-01-30 |
Vertex Pharmaceuticals Incorporated |
Analogues for the treatment or prevention of flavivirus infections
|
WO2011127350A1
(en)
|
2010-04-09 |
2011-10-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
EP2575819A4
(en)
|
2010-06-04 |
2013-11-27 |
Enanta Pharm Inc |
INHIBITORS OF HEPATITIS C VIRUS
|
NZ605440A
(en)
|
2010-06-10 |
2014-05-30 |
Abbvie Bahamas Ltd |
Solid compositions comprising an hcv inhibitor
|
EP2585448A1
(en)
|
2010-06-28 |
2013-05-01 |
Vertex Pharmaceuticals Incorporated |
Compounds and methods for the treatment or prevention of flavivirus infections
|
MX2012014918A
(es)
|
2010-06-28 |
2013-04-08 |
Vertex Pharma |
Compuestos y metodos para tratamiento o prevencion de infecciones por flavivirus.
|
CA2805440A1
(en)
|
2010-07-26 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
|
CN103180310B
(zh)
|
2010-07-26 |
2015-11-25 |
爱尔兰詹森科学公司 |
作为hcv抑制剂的杂二环衍生物
|
US20120195857A1
(en)
*
|
2010-08-12 |
2012-08-02 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
WO2012021704A1
(en)
|
2010-08-12 |
2012-02-16 |
Enanta Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
JP2013534249A
(ja)
|
2010-08-17 |
2013-09-02 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス科ウイルス感染の処置または予防のための化合物および方法
|
EP2963034A1
(en)
*
|
2010-08-26 |
2016-01-06 |
RFS Pharma, LLC. |
Potent and selective inhibitors of hepatitis c virus
|
US8822520B2
(en)
|
2010-09-22 |
2014-09-02 |
Presidio Pharmaceuticals, Inc. |
Substituted bicyclic HCV inhibitors
|
WO2012050918A2
(en)
|
2010-09-29 |
2012-04-19 |
Presidio Pharmaceutical, Inc. |
Tricyclic fused ring inhibitors of hepatitis c
|
WO2012041227A1
(en)
*
|
2010-09-29 |
2012-04-05 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds for treating hepatitis c viral infection
|
WO2012050848A1
(en)
|
2010-09-29 |
2012-04-19 |
Schering Corporation |
Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
|
WO2012058125A1
(en)
|
2010-10-26 |
2012-05-03 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of hepatitis c virus
|
CA2814534A1
(en)
|
2010-11-04 |
2012-05-10 |
Theravance, Inc. |
Novel inhibitors of hepatitis c virus
|
CA2817840A1
(en)
|
2010-11-17 |
2012-05-24 |
Gilead Sciences, Inc. |
Antiviral compounds
|
RU2452735C1
(ru)
*
|
2010-11-30 |
2012-06-10 |
Александр Васильевич Иващенко |
Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
|
US20150232455A1
(en)
*
|
2010-12-15 |
2015-08-20 |
Allan C. Krueger |
Anti-viral compounds
|
WO2012083061A2
(en)
*
|
2010-12-15 |
2012-06-21 |
Abbott Laboratories |
Anti-viral compounds
|
US9173887B2
(en)
|
2010-12-22 |
2015-11-03 |
Abbvie Inc. |
Hepatitis C inhibitors and uses thereof
|
WO2012088438A1
(en)
*
|
2010-12-22 |
2012-06-28 |
Eutropics Pharmaceuticals, Inc. |
Compositions and methods useful for treating diseases
|
US8552047B2
(en)
|
2011-02-07 |
2013-10-08 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2012122716A1
(en)
*
|
2011-03-17 |
2012-09-20 |
Merck Sharp & Dohme Corp. |
Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
|
US9546160B2
(en)
|
2011-05-12 |
2017-01-17 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US10201584B1
(en)
|
2011-05-17 |
2019-02-12 |
Abbvie Inc. |
Compositions and methods for treating HCV
|
WO2012158861A2
(en)
|
2011-05-18 |
2012-11-22 |
Enanta Pharmaceuticals, Inc. |
Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives
|
WO2013016491A1
(en)
|
2011-07-26 |
2013-01-31 |
Vertex Pharmaceuticals Incorporated |
Thiophene compounds
|
WO2013016499A1
(en)
|
2011-07-26 |
2013-01-31 |
Vertex Pharmaceuticals Incorporated |
Methods for preparation of thiophene compounds
|
FR2981071B1
(fr)
*
|
2011-10-10 |
2014-02-07 |
Centre Nat Rech Scient |
Synthese versatile et stereospecifique d'acides amines gamma,delta-insatures par la reaction de wittig
|
WO2013030750A1
(en)
|
2011-09-01 |
2013-03-07 |
Lupin Limited |
Antiviral compounds
|
EP2755981A4
(en)
|
2011-09-14 |
2015-03-25 |
Merck Sharp & Dohme |
HETEROCYCLIC COMPOUNDS CONTAINING SILYL AND METHODS OF USING THE SAME FOR TREATING VIRAL DISEASES
|
AU2012308295B2
(en)
|
2011-09-16 |
2017-10-26 |
Gilead Pharmasset Llc |
Methods for treating HCV
|
US8957048B2
(en)
|
2011-10-06 |
2015-02-17 |
Allergan, Inc. |
Compositions for the treatment of dry eye
|
AU2012332358B2
(en)
|
2011-11-03 |
2017-07-13 |
Theravance Biopharma R&D Ip, Llc |
Rod -like hepatitis C virus inhibitors containing the fragement {2- [4- (bi phenyl - 4 - yl) - 1H - imidazo - 2 - yl] pyrrolidine - 1 - carbonlymethyl} amine
|
SI2907816T1
(sl)
|
2011-11-16 |
2018-10-30 |
Gilead Pharmasset Llc |
Kondenzirani imidazolilimidazoli kot protivirusni sestavki
|
SG11201402899TA
(en)
|
2011-12-06 |
2014-07-30 |
Univ Leland Stanford Junior |
Methods and compositions for treating viral diseases
|
US9907826B2
(en)
|
2011-12-07 |
2018-03-06 |
Allergan, Inc. |
Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
|
RU2014131017A
(ru)
|
2011-12-28 |
2016-02-20 |
ЯНССЕН Ар ЭНД Ди АЙРЛЭНД |
Хиназолиноновые производные в качестве ингибиторов hcv
|
RU2621734C1
(ru)
*
|
2011-12-28 |
2017-06-07 |
Янссен Сайенсиз Айрлэнд Юси |
Гетеробициклические производные в качестве ингибиторов hcv
|
US9034832B2
(en)
|
2011-12-29 |
2015-05-19 |
Abbvie Inc. |
Solid compositions
|
US9326973B2
(en)
|
2012-01-13 |
2016-05-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
IN2014MN01547A
(ru)
|
2012-02-10 |
2015-05-08 |
Lupin Ltd |
|
US9012427B2
(en)
|
2012-03-22 |
2015-04-21 |
Alios Biopharma, Inc. |
Pharmaceutical combinations comprising a thionucleotide analog
|
JP6069491B2
(ja)
|
2012-04-25 |
2017-02-01 |
セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー |
C型肝炎ウイルス阻害剤としてのピペラジン−ピペリジン化合物
|
CN104302636B
(zh)
|
2012-04-25 |
2017-03-29 |
施万生物制药研发Ip有限责任公司 |
C型肝炎病毒抑制剂
|
US20130309196A1
(en)
|
2012-05-16 |
2013-11-21 |
Gilead Sciences, Inc. |
Antiviral compounds
|
MX2015000129A
(es)
*
|
2012-07-10 |
2015-04-14 |
Ares Trading Sa |
Derivados de pirimidin pirazolilo.
|
TWI610916B
(zh)
*
|
2012-08-03 |
2018-01-11 |
廣東東陽光藥業有限公司 |
作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
|
US9802949B2
(en)
|
2012-11-29 |
2017-10-31 |
Sunshine Lake Pharma Co., Ltd. |
Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
|
US9416139B2
(en)
|
2012-11-29 |
2016-08-16 |
Sunshine Lake Pharma Co., Ltd. |
Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof
|
LT2950786T
(lt)
|
2013-01-31 |
2020-03-10 |
Gilead Pharmasset Llc |
Dviejų antivirusinių junginių preparatų kompozicija
|
RU2507201C1
(ru)
*
|
2013-02-07 |
2014-02-20 |
Александр Васильевич Иващенко |
Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
|
US20150065439A1
(en)
|
2013-02-28 |
2015-03-05 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions
|
US11484534B2
(en)
|
2013-03-14 |
2022-11-01 |
Abbvie Inc. |
Methods for treating HCV
|
US20150023913A1
(en)
|
2013-07-02 |
2015-01-22 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US9717712B2
(en)
|
2013-07-02 |
2017-08-01 |
Bristol-Myers Squibb Company |
Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
|
WO2015009744A1
(en)
|
2013-07-17 |
2015-01-22 |
Bristol-Myers Squibb Company |
Combinations comprising biphenyl derivatives for use in the treatment of hcv
|
ES2792503T3
(es)
|
2013-08-27 |
2020-11-11 |
Gilead Pharmasset Llc |
Formulación combinada de dos compuestos antivirales
|
WO2015065817A1
(en)
|
2013-10-30 |
2015-05-07 |
Merck Sharp & Dohme Corp. |
Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
|
WO2015089810A1
(en)
|
2013-12-20 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases
|
EP3089757A1
(en)
|
2014-01-03 |
2016-11-09 |
AbbVie Inc. |
Solid antiviral dosage forms
|
WO2015110048A1
(en)
|
2014-01-23 |
2015-07-30 |
Sunshine Lake Pharma Co., Ltd. |
Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
|
TWI721947B
(zh)
|
2014-06-11 |
2021-03-21 |
美商基利法瑪席特有限責任公司 |
抗病毒化合物的固態形式
|
EP3191453B1
(en)
|
2014-09-09 |
2019-10-23 |
Bristol-Myers Squibb Company |
Phenyl-(aza)cycloalkyl carboxylic acid gpr120 modulators
|
US10617675B2
(en)
|
2015-08-06 |
2020-04-14 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
GB2552919A
(en)
*
|
2015-11-18 |
2018-02-21 |
Azad Pharmaceutical Ingredients Ag |
Stable amorphous form of daclatasvir
|
RU2650610C1
(ru)
|
2017-02-28 |
2018-04-16 |
Васильевич Иващенко Александр |
Противовирусная композиция и способ ее применения
|
EP3891508A1
(en)
|
2018-12-04 |
2021-10-13 |
Bristol-Myers Squibb Company |
Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
|
CN109456375B
(zh)
*
|
2018-12-11 |
2019-10-22 |
枣庄学院 |
一种抑制丙肝病毒的含单糖基杂环类化合物及制备方法
|